21.36

3.70% -0.82

Bicycle Therapeutics Plc ADR (BCYC)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$22.18

Aprire:

$22.18

Volume 24 ore:

121.53K

Capitalizzazione di mercato:

$813.24M

Reddito:

$26.98M

Utile/perdita netta:

$-180.66M

Rapporto P/E:

-4.5641

EPS:

-4.68

Flusso di cassa netto:

$-63.56M

1 W Prestazione:

-6.68%

1M Prestazione:

-2.11%

6M Prestazione:

+54.22%

1 anno Prestazione:

-11.48%

Intervallo 1D:

$21.29

$22.18

Portata 52W:

$12.54

$28.91

Bicycle Therapeutics Plc ADR Stock (BCYC) Company Profile

Nome

Bicycle Therapeutics Plc ADR

Settore

Healthcare (1209)

Industria

Biotechnology (699)

Telefono

44 1223 497 415

Indirizzo

Babraham Research Campus, Building 900, Cambridge

Dipendente

Cinguettio

@Bicycle_tx

Prossima data di guadagno

2024-05-16

Ultimi documenti SEC

BCYC's Discussions on Twitter

Bicycle Therapeutics Plc ADR Stock (BCYC) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-09-11	Aggiornamento	B. Riley Securities	Neutral → Buy
2022-08-31	Iniziato	Cowen	Outperform
2022-07-28	Iniziato	Barclays	Overweight
2022-07-06	Ripresa	Canaccord Genuity	Buy
2022-04-13	Downgrade	B. Riley Securities	Buy → Neutral
2022-04-07	Ripresa	Cantor Fitzgerald	Overweight
2022-02-14	Iniziato	Morgan Stanley	Equal-Weight
2021-12-17	Iniziato	SVB Leerink	Outperform
2021-12-09	Iniziato	Needham	Buy
2021-09-30	Iniziato	B. Riley Securities	Buy
2021-04-20	Iniziato	JMP Securities	Mkt Outperform
2020-10-12	Iniziato	Cantor Fitzgerald	Overweight
2020-06-12	Iniziato	Oppenheimer	Outperform
2020-04-17	Iniziato	H.C. Wainwright	Buy
2019-11-14	Iniziato	ROTH Capital	Buy
2019-09-11	Aggiornamento	Goldman	Neutral → Buy
2019-06-17	Iniziato	Canaccord Genuity	Buy
2019-06-17	Iniziato	Goldman	Neutral
2019-06-17	Iniziato	Jefferies	Buy
2019-06-17	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Bicycle Therapeutics Plc ADR Borsa (BCYC) Ultime notizie

Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View - Yahoo Singapore News

Yahoo Singapore News

Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Yahoo Finance

Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?

Zacks Investment Research

Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? - Yahoo Finance

Yahoo Finance

Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting - Investing.com South Africa

Investing.com South Africa

Insider Selling: Hannay Michael Charles Ferguso, Bicycle Therapeutics Plc ADR [BCYC] CHIEF PROD & SUPPLY ... - Knox Daily

Knox Daily

Bicycle Therapeutics Plc ADR Azioni (BCYC) Dati Finanziari